Aditxt, Inc. - Common Stock (ADTX)

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

Aditxt, Inc. requests that their press release NewsItemId: 20250417385764 “Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™” be killed.

Aditxt (NASDAQ: ADTX) announced that Dr. Charles Howe of the Mayo Clinic will join the Company’s Weekly Update on May 2, 2025, to discuss key findings from a newly announced preclinical study of ADI-100, the lead therapeutic candidate from Aditxt’s subsidiary, Adimune Inc. The update will also feature Dr. Shahrokh Shabahang, Aditxt’s Chief Innovation Officer, and Dr. Friedrich Kapp, Co-CEO of Adimune, highlighting the latest advancements in immune modulation therapy.

Aditxt (NASDAQ: ADTX) announced that its subsidiary Pearsanta has received Institutional Review Board approval to initiate a clinical study evaluating the Mitomic Endometriosis Test (MET), a blood-based diagnostic aimed at early detection of endometriosis. The study will enroll up to 1,000 participants beginning in May 2025 and compare MET results to laparoscopic diagnoses, the current standard. Designed to detect mitochondrial DNA deletions, MET offers a non-invasive approach that could reduce diagnostic delays impacting millions of women globally. Results may support the test’s launch as a Laboratory Developed Test from Pearsanta’s certified lab.

Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has received Institutional Review Board (IRB) approval from WCG Clinical to initiate a prospective clinical study evaluating the Mitomic® Endometriosis Test (MET), a novel blood-based diagnostic designed to aid in the early detection of endometriosis.

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced that today’s Aditxt Weekly Update will provide key updates on recent events, including:

Aditxt (NASDAQ: ADTX) announced it has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2), eliminating the need for a previously scheduled hearing with the exchange’s Hearings Panel. The company’s stock will continue trading on the Nasdaq Capital Market under the ticker ADTX as it advances health innovation efforts targeting autoimmunity, cancer, and other major health challenges.

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, announced today that it received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). The hearing before the Hearings Panel scheduled to take place on April 22, 2025, has been cancelled. The Company’s common stock will continue to trade on the Nasdaq Capital Market under the symbol ADTX.

Aditxt (NASDAQ: ADTX), a social innovation platform accelerating health breakthroughs, announced that Don Cilla, Pharm.D., M.B.A., CEO of Appili Therapeutics, will join its Weekly Update on April 4 at 11:30 a.m. ET. The session will spotlight the growing need for infectious disease treatments and explore how partnerships like Aditxt and Appili’s can fast-track health innovations. The discussion will also detail Appili’s $33.2 million in non-dilutive funding, $117 million in new applications, and updates to its U.S. Air Force Academy agreement supporting ATI-1701, a biodefense vaccine candidate.

Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that Don Cilla, Pharm.D., M.B.A., President and CEO of Appili Therapeutics Inc. ("Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, will be joining at the upcoming Aditxt Weekly Update. The event, scheduled on April 4 at 11:30 am ET, will highlight the urgent need for infectious disease treatments, and the role of partnerships in accelerating promising health innovations.

Aditxt (NASDAQ: ADTX), a social innovation platform focused on accelerating health technologies, announced that its latest Aditxt Weekly Update will spotlight the recent acquisition of the CaSe Platform by its subsidiary, Pearsanta, Inc. The proprietary technology, based on adductomics, is engineered to detect early DNA changes that could lead to cancer and other diseases. The discussion will emphasize how the CaSe Platform supports Pearsanta’s mission of advancing early detection and prevention in oncology. Featured participants include Dr. Shahrokh Shabahang of Aditxt, Chris Mitton of Pearsanta, and Dr. Roger Giese, the platform’s co-inventor.

Aditxt, Inc. (NASDAQ: ADTX), (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced that today’s Aditxt Weekly Update will focus on the recent acquisition of the CaSe Platform by its subsidiary, Pearsanta, Inc. (“Pearsanta”). The proprietary technology is based on adductomics and is designed to assess early DNA changes that may lead to mutations associated with cancer and other illnesses. The discussion will explore the platform’s role in advancing Pearsanta’s mission to address cancer through early detection and prevention.

Aditxt (NASDAQ: ADTX) announced that its subsidiary, Pearsanta, Inc., has acquired key patents for adductomics-based DNA damage detection in a $1 million stock transaction. The move expands Pearsanta’s capabilities in early cancer risk assessment, complementing its existing Mitomic® Technology. The acquired technology detects DNA adducts—early markers of carcinogen exposure—allowing for potential cancer prevention strategies before permanent mutations develop. Pearsanta plans to advance clinical validation and regulatory pathways over the next two to three years, aiming to commercialize the diagnostics through CLIA/CAP-certified labs.

Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has acquired key patents related to adductomics-based DNA damage detection, which it believes will further strengthen its position in the cancer prevention-focused diagnostic industry.

Aditxt (NASDAQ: ADTX) through its wholly owned subsidiary Adivir, Inc., is progressing with its planned acquisition of Appili Therapeutics (TSX: APLI; OTCPink: APLIF) under a court-approved plan of arrangement. Appili shareholders have overwhelmingly approved the transaction, and the company has secured all necessary court approvals. The closing remains contingent on Aditxt securing sufficient financing, with an extension granted until March 31, 2025, in exchange for a $250,000 payment. Separately, Appili has applied for up to $117.5 million in U.S. federal funding to support infectious disease treatments, further positioning the company within the critical biopharmaceutical sector.

Aditxt (NASDAQ: ADTX), a health innovation platform, provided a corporate update highlighting progress across its subsidiaries and acquisition initiatives. The company remains focused on advancing its autoimmune treatment subsidiary Adimune , precision diagnostics unit Pearsanta , and neurological monitoring subsidiary Adivue , while also pursuing strategic acquisitions, including Appili Therapeutics and Evofem Biosciences. Additionally, Aditxt will launch its Aditxt Weekly Update series on March 21, 2025, featuring CEO Amro Albanna and Evofem CEO Saundra Pelletier, aiming to enhance transparency and investor engagement.

Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today provided a corporate update outlining recent achievements and strategic milestones across its subsidiaries and strategic acquisition initiatives. In addition, the Company will be launching Aditxt Weekly Updates, starting Friday March 21, 2025, and continuing throughout the second quarter of 2025.

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, announced today that it will effect a 1-for-250 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on March 17, 2025, the Company’s common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company’s stockholders at the special meeting held on February 28, 2025, with the final ratio determined by the Company’s board of directors.

As market volatility continues, small-cap stocks are attracting investor attention with groundbreaking technological advancements, biotech breakthroughs, and resource expansion projects . Companies across multiple industries are making major strides, positioning themselves for growth and long-term value creation . Here are some of the most compelling penny stocks that are making headlines

Aditxt (NASDAQ: ADTX) provided an update on its subsidiary, Adimune, Inc., and the progress of ADI-100, an investigational gene therapy targeting autoimmune diseases such as psoriasis, Type 1 diabetes, and Stiff Person Syndrome. Adimune has completed preclinical studies and is preparing for drug substance shipment in March, with clinical trials planned in Germany and an FDA pre-IND meeting anticipated in the second quarter of 2024. ADI-100 is designed to restore immune tolerance without immunosuppression, marking a potential breakthrough in autoimmune disease treatment.

Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today provided an update on its subsidiary, Adimune, Inc., (“Adimune”) and its progress in advancing ADI-100, an investigational product candidate to be studied in patients with Psoriasis, Type I Diabetes (T1D) and Stiff Person Syndrome.

Aditxt (NASDAQ: ADTX) announced that its subsidiary, Pearsanta, has engaged Dominari Securities LLC as the lead underwriter for its planned initial public offering (IPO), expected in the second half of 2025. The IPO aims to support Pearsanta’s commercialization of its Mitomic® Technology platform for early cancer detection, leveraging mitochondrial DNA biomarkers for non-invasive diagnostics. Funds raised will facilitate the U.S. launch of Laboratory Developed Tests (LDTs) and drive global expansion through regulatory approvals and distribution partnerships.

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. (“Pearsanta”), has engaged Dominari Securities LLC as lead underwriter for Pearsanta’s planned initial public offering (IPO). The proposed IPO, advised by Dominari Securities, is intended to support Pearsanta’s U.S. and international commercial launch efforts and further advance its Mitomic® Technology platform for early cancer detection and diagnosis.

Aditxt (NASDAQ: ADTX), a social innovation platform focused on advancing health innovations, will host a virtual Fireside Chat on Feb. 21, 2025, at 11:30 a.m. ET. CEO Amro Albanna will provide updates on the company’s subsidiaries, potential transactions, and pipeline advancements. The discussion will highlight Adimune, Inc.’s progress in autoimmunity treatments, including Type 1 Diabetes and Psoriasis, as well as Pearsanta’s early cancer detection program and its planned 2025 IPO. Participants can submit questions via email by Feb. 20 at 5 p.m. ET.

Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced that it will host a virtual Fireside Chat on Friday, February 21, 2025, at 11:30 AM Eastern Time. The event will feature Amro Albanna, CEO of Aditxt, who will provide updates on key corporate developments, including the status of current subsidiaries, potential transactions, and notable advancements in the Company's pipeline.